096530.KQ
Seegene, Inc. [096530.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
096530.KQ Stock Summary
Top 10 Correlated ETFs
096530.KQ
Top 10 Correlated Stocks
096530.KQ
In the News
096530.KQ Financial details
Company Rating
Buy
Market Cap
1017.57B
Income
669.01M
Revenue
367.38B
Book val./share
22319.94
Cash/share
11311.82
Dividend
800
Dividend %
3.35%
Employees
63
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-125.54
Forward P/E
-
PEG
12.6
P/S
2.68
P/B
1.07
P/C
1.9
P/FCF
24.4
Quick Ratio
3.17
Current Ratio
5.16
Debt / Equity
0.09
LT Debt / Equity
0
-
-
EPS (TTM)
14.2
EPS next Y
-
EPS next Q
-
EPS this Y
-99.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-51.21%
Revenue last 5Y
24.68%
Revenue Q/Q
9.39%
EPS Q/Q
-225.96%
-
-
-
-
SMA20
-10.31%
SMA50
-13.62%
SMA100
2.99%
Inst Own
0%
Inst Trans
0%
ROA
-1%
ROE
-1%
ROC
-0.05%
Gross Margin
46%
Oper. Margin
-12%
Profit Margin
-2%
Payout
-442%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
19040.0-30600.0
52W High
-29.74%
52W Low
+12.92%
RSI
30
Rel Volume
0.24
Avg Volume
627.2K
Volume
150.13K
Perf Week
-4.66%
Perf Month
-8.32%
Perf Quarter
6.97%
Perf Half Y
5.65%
-
-
-
-
Beta
-1.167
-
-
Volatility
557.69%, 1336.83%
Prev Close
2.38%
Price
21500
Change
2.14%
096530.KQ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.35K | 21.65K | 26.47K | 16.81K | 7.79K | |
| Net income per share | 513.08 | 9.66K | 10.36K | 3.59K | 14.19 | |
| Operating cash flow per share | 627.94 | 7.37K | 6.45K | 6.28K | 2.01K | |
| Free cash flow per share | 535.87 | 4K | 5.17K | 4.85K | 1.34K | |
| Cash per share | 1.27K | 6.18K | 9.14K | 11.89K | 11.05K | |
| Book value per share | 2.93K | 12.41K | 20.88K | 22.6K | 21.8K | |
| Tangible book value per share | 2.85K | 12.31K | 20.7K | 22.17K | 21.27K | |
| Share holders equity per share | 2.93K | 12.41K | 20.88K | 22.6K | 21.8K | |
| Interest debt per share | 212.19 | 1.74K | 1.99K | 2.13K | 2.17K | |
| Market cap | 796.65B | 5016.45B | 3159.64B | 1381.42B | 1084.39B | |
| Enterprise value | 762.66B | 4811.37B | 2886.58B | 1019.26B | 1035.81B | |
| P/E ratio | 29.87 | 9.99 | 5.89 | 7.58 | 1.62K | |
| Price to sales ratio | 6.53 | 4.46 | 2.3 | 1.62 | 2.95 | |
| POCF ratio | 24.41 | 13.09 | 9.46 | 4.33 | 11.42 | |
| PFCF ratio | 28.6 | 24.13 | 11.79 | 5.6 | 17.2 | |
| P/B Ratio | 5.22 | 7.77 | 2.92 | 1.2 | 1.06 | |
| PTB ratio | 5.22 | 7.77 | 2.92 | 1.2 | 1.06 | |
| EV to sales | 6.25 | 4.28 | 2.11 | 1.19 | 2.82 | |
| Enterprise value over EBITDA | 23.39 | 6.94 | 4.11 | 4.27 | 29.05 | |
| EV to operating cash flow | 23.36 | 12.56 | 8.64 | 3.2 | 10.91 | |
| EV to free cash flow | 27.38 | 23.14 | 10.77 | 4.13 | 16.43 | |
| Earnings yield | 0.03 | 0.1 | 0.17 | 0.13 | 0 | |
| Free cash flow yield | 0.03 | 0.04 | 0.08 | 0.18 | 0.06 | |
| Debt to equity | 0.07 | 0.14 | 0.09 | 0.09 | 0.09 | |
| Debt to assets | 0.05 | 0.08 | 0.07 | 0.07 | 0.08 | |
| Net debt to EBITDA | -1.04 | -0.3 | -0.39 | -1.52 | -1.36 | |
| Current ratio | 4.91 | 2.09 | 3.67 | 5.3 | 4.83 | |
| Interest coverage | 46.17 | 483.95 | 176.6 | 33.23 | -4.82 | |
| Income quality | 1.22 | 0.76 | 0.62 | 1.75 | 141.9 | |
| Dividend Yield | 0 | 0 | 0.02 | 0.04 | 0.04 | |
| Payout ratio | 0 | 0.01 | 0.13 | 0.28 | 56.91 | |
| Sales general and administrative to revenue | 0.06 | 0.02 | 0.04 | 0.05 | 0.1 | |
| Research and developement to revenue | 0.08 | 0.02 | 0.06 | 0.11 | 0.2 | |
| Intangibles to total assets | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.15 | -0.46 | -0.2 | -0.23 | -0.34 | |
| Capex to revenue | -0.04 | -0.16 | -0.05 | -0.08 | -0.09 | |
| Capex to depreciation | -0.47 | -10.05 | -1.82 | -1.25 | -0.49 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.01 | |
| Graham number | 5.82K | 51.95K | 69.76K | 42.7K | 2.64K | |
| ROIC | 0.13 | 0.67 | 0.42 | 0.11 | -0.01 | |
| Return on tangible assets | 0.14 | 0.46 | 0.36 | 0.13 | 0 | |
| Graham Net | 1.39K | 3.33K | 8.4K | 10.48K | 9.31K | |
| Working capital | 110.3B | 407.58B | 766.81B | 732.31B | 621.33B | |
| Tangible asset value | 148.02B | 639.69B | 1072.14B | 1125.84B | 1003.03B | |
| Net current asset value | 95.61B | 334.71B | 647.47B | 662.01B | 562.43B | |
| Invested capital | 0.07 | 0.14 | 0.09 | 0.09 | 0.09 | |
| Average receivables | 46.35B | 180.21B | 327.49B | 233.57B | 106.49B | |
| Average payables | 9.53B | 47.55B | 66.49B | 34.89B | 25.07B | |
| Average inventory | 21.13B | 78.89B | 176.79B | 186.33B | 147.92B | |
| Days sales outstanding | 158.89 | 99.7 | 92.56 | 51.1 | 92.87 | |
| Days payables outstanding | 54.64 | 113.14 | 53.11 | 22.96 | 50.23 | |
| Days of inventory on hand | 135.57 | 179.73 | 250.82 | 149.04 | 268.21 | |
| Receivables turnover | 2.3 | 3.66 | 3.94 | 7.14 | 3.93 | |
| Payables turnover | 6.68 | 3.23 | 6.87 | 15.9 | 7.27 | |
| Inventory turnover | 2.69 | 2.03 | 1.46 | 2.45 | 1.36 | |
| ROE | 0.17 | 0.78 | 0.5 | 0.16 | 0 | |
| Capex per share | -92.07 | -3.37K | -1.28K | -1.43K | -676.17 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.47K | 1.84K | 1.8K | 1.98K | 2.18K | |
| Net income per share | 52 | 41.98 | -53.89 | -100.58 | 126.69 | |
| Operating cash flow per share | 586.11 | 757.61 | 224.26 | 431.53 | 592.31 | |
| Free cash flow per share | 329.46 | 569.5 | 75.41 | 268.83 | 416.26 | |
| Cash per share | 12.14K | 11.71K | 11.26K | 11.4K | 11.31K | |
| Book value per share | 23.08K | 22.25K | 22.43K | 22.39K | 22.32K | |
| Tangible book value per share | 22.64K | 21.77K | 21.92K | 21.88K | 21.78K | |
| Share holders equity per share | 23.08K | 22.25K | 22.43K | 22.39K | 22.32K | |
| Interest debt per share | 2.1K | 2.04K | 2.1K | 2.11K | 2.12K | |
| Market cap | 1352.59B | 1212.08B | 968.36B | 992.68B | 1059.01B | |
| Enterprise value | 990.43B | 1094.15B | 983.11B | 956.7B | 1010.44B | |
| P/E ratio | 130.76 | 147.67 | -95.33 | -53.07 | 45.39 | |
| Price to sales ratio | 11.01 | 13.46 | 11.4 | 10.8 | 10.54 | |
| POCF ratio | 46.41 | 32.73 | 91.63 | 49.47 | 38.83 | |
| PFCF ratio | 82.56 | 43.55 | 272.52 | 79.42 | 55.25 | |
| P/B Ratio | 1.18 | 1.11 | 0.92 | 0.95 | 1.03 | |
| PTB ratio | 1.18 | 1.11 | 0.92 | 0.95 | 1.03 | |
| EV to sales | 8.06 | 12.15 | 11.58 | 10.41 | 10.05 | |
| Enterprise value over EBITDA | 30.05 | 545.11 | 143.41 | 147.37 | 49.77 | |
| EV to operating cash flow | 33.98 | 29.55 | 93.03 | 47.68 | 37.05 | |
| EV to free cash flow | 60.45 | 39.31 | 276.67 | 76.54 | 52.72 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0.01 | |
| Free cash flow yield | 0.01 | 0.02 | 0 | 0.01 | 0.02 | |
| Debt to equity | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Debt to assets | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | |
| Net debt to EBITDA | -10.99 | -58.75 | 2.15 | -5.54 | -2.39 | |
| Current ratio | 5.3 | 4.76 | 5.25 | 5.16 | 4.83 | |
| Interest coverage | 11.43 | -9.15 | -6.57 | -5.95 | 2.25 | |
| Income quality | 11.27 | 18.05 | -4.16 | -4.29 | 4.68 | |
| Dividend Yield | 0.01 | 0 | 0.02 | 0.01 | 0.01 | |
| Payout ratio | 3.9 | 0 | -7.67 | -1.99 | 1.59 | |
| Sales general and administrative to revenue | 0.09 | 0.09 | 0.08 | 0.1 | 0.11 | |
| Research and developement to revenue | 0.16 | 0.22 | 0.2 | 0.19 | 0.17 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.44 | -0.25 | -0.66 | -0.38 | -0.3 | |
| Capex to revenue | -0.1 | -0.1 | -0.08 | -0.08 | -0.08 | |
| Capex to depreciation | -0.76 | -0.58 | -0.42 | -0.46 | -0.48 | |
| Stock based compensation to revenue | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham number | 5.2K | 4.58K | 5.22K | 7.12K | 7.98K | |
| ROIC | 0 | 0 | -0.01 | -0.01 | 0 | |
| Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
| Graham Net | 10.7K | 9.99K | 9.94K | 9.81K | 9.53K | |
| Working capital | 732.31B | 667.68B | 652.38B | 639.88B | 621.33B | |
| Tangible asset value | 1125.84B | 1063.8B | 1033.1B | 1017.25B | 1003.03B | |
| Net current asset value | 662.01B | 599.86B | 589.74B | 580.6B | 562.43B | |
| Invested capital | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Average receivables | 132.11B | 113.71B | 106.92B | 100.78B | 94.55B | |
| Average payables | 27.65B | 27.12B | 23.74B | 17.69B | 21.77B | |
| Average inventory | 157.94B | 159.3B | 155.13B | 142.31B | 136.19B | |
| Days sales outstanding | 87.57 | 107.86 | 112.26 | 93.66 | 83.7 | |
| Days payables outstanding | 43.19 | 53.95 | 34.85 | 34.33 | 51.09 | |
| Days of inventory on hand | 280.35 | 289.64 | 296.67 | 260.33 | 272.77 | |
| Receivables turnover | 1.03 | 0.83 | 0.8 | 0.96 | 1.08 | |
| Payables turnover | 2.08 | 1.67 | 2.58 | 2.62 | 1.76 | |
| Inventory turnover | 0.32 | 0.31 | 0.3 | 0.35 | 0.33 | |
| ROE | 0 | 0 | 0 | 0 | 0.01 | |
| Capex per share | -256.66 | -188.11 | -148.86 | -162.71 | -176.05 |
096530.KQ Frequently Asked Questions
What is Seegene, Inc. stock symbol ?
Seegene, Inc. is a KR stock and trading under the symbol 096530.KQ
What is Seegene, Inc. stock quote today ?
Seegene, Inc. stock price is $21500 today.
Is Seegene, Inc. stock public?
Yes, Seegene, Inc. is a publicly traded company.
Company Profile
- Volume Average 627.2K
- Market Capitalization 1017.57B
- Employee 63
- CEO Dr. Jong-Yoon Chun
- Headquarters Seoul,KR
- IPO Date 2010-09-10
-
Website
https://www.seegene.com 
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection products; drug resistance products; Magicplex sepsis real-time test for the detection and identification of sepsis causing pathogens; and meningitis detection products. The company also provides other products for the detection of six SNPs in factor II, factor V, and MTHFR genes; BRAF mutation characteristic for papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy, H&E slides, and paraffin-embedded tissues; Apolipoprotein E genotypes; and BCR/ABL fusion gene from blood and whole bone marrow. In addition, it offers PCR machines; vial cap management systems; nucleic acid extraction systems; automated liquid handling workstations from nucleic acid extraction to PCR setup; and real-time PCR detection systems. Seegene, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
